

Rejuvine Life Sciences, Inc.

**FINANCIAL STATEMENTS
(Unaudited)**

As of December 31, 2023

Rejuvine Life Sciences, Inc.

Financial Statements

As of December 31, 2023

Index to Reviewed Financial Statements

Table of Contents	Page
Independent Accountant Review Report	3
Balance Sheet	4
Income Statement	5
Changes in Equity Statement	6
Cash Flow Statement	7
Notes to the Financial Statements	8



INDEPENDENT ACCOUNTANT REVIEW REPORT

March 18, 2024

The Board of Directors

Rejuvine Life Sciences, Inc.

65 I N. Broad St., Suite 201

Middletown DE 19709

We have reviewed the accompanying balance sheet of Rejuvine Life Sciences, Inc. (the company) as of As of December 31, 2023, and the related statement of income, statement of changes in owners' equity and statement of cash flows for the period then ended, and the related notes to the financial statements.

A review includes primary applying analytical procedures to management's financial data and making inquiries of the company's management. A review is less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

MANAGEMENT'S RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

Management is responsible for the preparation and fair presentation of these financial statements in accordance with principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

ACCOUNTANT RESPONSIBILITY

Our responsibility is to conduct the review in accordance with the Statement on Standards of Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of material modifications that should be made in the financial statements for them to be in accordance with the accounting principles generally accepted in the United States of America. We believe that the results of our procedures provide a reasonable basis for our report.

ACCOUNTANT'S CONCLUSION

Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in accordance with the accounting principles generally accepted in the United States of America.

EMPHASIS OF MATTER

The accompanying financial statements have been prepared assuming that the company will continue as going concern. As discussed in note 5 the company has accumulated deficit that raises substantial doubt about the company's ability to continue as going concern. Management plans also discussed in note 5 and 4.

Amjad Abu Khamis
Mar. 18, 2024

Certified Public Accountant, NH 08224
CF Audits LLC
159 Main St. STE 100
Nashua NH 03060
cpa@cfaudits.com

Rejuvine Life Sciences, Inc.
Balance Sheet Statement (Unaudited)

As of December 31, 2023

ASSETS	2023
Current Assets	
Cash in Hand	28,950
Bank Account	2,000
Produced Inventory	94,750
Raw Materials Inventory	79,352
Total Current Assets	205,052
Non-Current Assets	
Note Receivable - Shareholder	4,000,000
Total Non-Current Assets	4,000,000
TOTAL ASSETS	4,205,052
LIABILITIES AND EQUITY	
Total Current Liabilities	-
Non-Current Liabilities	
Notes Payable	3,910,000
Total Non-Current Liabilities	3,910,000
TOTAL LIABILITIES	3,910,000
Equity	
Common Shares	-
Additional Paid-In Capital	500,552
Retained Earnings (Deficit)	(205,500)
TOTAL EQUITY	295,052
TOTAL LIABILITIES AND EQUITY	4,205,052

The accompanying notes are an integral part of these financial statements

Rejuvine Life Sciences, Inc.

Income Statement (Unaudited)

For the period ended as of December 31, 2023

	2023
Net Sales	9,306
Less: Cost of Goods Sold	(5,076)
Gross Revenue	4,230
Operating Expenses	
Professional Services Expense	147,000
Research and Development Expense	10,975
Amortization of Inventory	18,950
Travels & Accommodations Expense	8,844
General & Administrative Expense	6,684
Tax Expense	17,277
Less: Total Operating Expenses	(209,730)
Net Income (Loss)	(205,500)

The accompanying notes are an integral part of these financial statements

Rejuvine Life Sciences, Inc.

Statement of Changes in Equity (Unaudited)

For the period ended as of December 31, 2023

	Common Shares	Additional Paid- in Capital	Retained Earnings (Deficit)	Total
Balance as of February 9, 2023	-	-	-	-
Capital Contributions	-	500,552	-	500,552
Net Income (Loss)	-	-	(205,500)	295,052
Balance as of December 31, 2023	-	500,552	(205,500)	295,052

The accompanying notes are an integral part of these financial statements

Rejuvine Life Sciences, Inc.

Statement of Cash Flow (Unaudited)

For the period ended as of December 31, 2023

OPERATING ACTIVITIES	2023
Net Income (Loss)	(205,500)
<i>Adjustments to Reconcile Net Income to Net Cash provided by operations:</i>	
Change in Inventory (Raw Materials and Produced)	(174,102)
Net cash (Used) by operating activities	(379,602)
Cash (Used) by Investing Activities	
Intellectual Property	(4,000,000)
Net Cash (Used) by Investing Activities	(4,000,000)
Cash Provided by Financing Activities	
Notes Payable	3,910,000
Additional Paid-In Capital	500,552
Net Cash Provided by Financing Activities	4,410,552
NET CASH INCREASE (DECREASE) FOR PERIOD	30,950
Cash at the beginning of the period	-
CASH AT END OF PERIOD	30,950

The accompanying notes are an integral part of these financial statements

Rejuvive Life Sciences, Inc.

Notes to the Financial Statements (Unaudited)

As of December 31, 2023

1. DESCRIPTION OF THE BUSINESS

Rejuvive Life Sciences, Inc. (the Company) was incorporated on February 9, 2023 in the state of Delaware. The company's mission is to deliver innovation that will help people to live healthier, longer lives and to expand the health span of human beings, enabling all of us to enjoy a higher quality of life in old age, and reducing the burden of age-related diseases.

At Rejuvive Life Sciences, we are proud to lead a company that is dedicated to developing and delivering scientifically validated herbal formulations that can help people overcome health challenges, improve their quality of life and recover from lifestyle disorders.

Our team of scientists and researchers are experts in the field of formulation development and pharmaceuticals, we're constantly working to develop new formulations that are backed by science, containing herbals, and have proven to be effective. We also have a strong focus on safety, and all of our products are manufactured in accordance with strict Good Manufacturing Practices (GMP) standards.

We are proud to offer a wide range of products for a variety of health conditions, including diabetes, women's health, and cardiovascular health. We also have a growing portfolio of products for general health and wellness.

Our products are available in India, Singapore, and the United States. We're committed to expanding our reach and making our products available to people all over the world

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1. Basis of Presentation

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States.

2.2. Use of Estimates

The preparation of financial statements in conformity with the U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management evaluates the estimates and assumptions based on historical experience and believes those estimates and assumptions are reasonable based on the information available to them.

Rejuvine Life Sciences, Inc.

Notes to the Financial Statements (Unaudited)

As of December 31, 2023

2.3. Cash

The Company deposits its cash with financial institutions that Management believes are of high credit quality. The Company's cash consists primarily of cash deposited in U.S. dollar denominated demand-deposit accounts.

2.4. Accounts Receivables and Allowance for Doubtful Accounts

Accounts receivables are stated at Net Realizable Value (NRV). On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance or if any accounts should be written off based on a past history of write offs, collections, and current credit conditions. A receivable is considered past due if the company has not received payments based on agreed-upon terms. The company generally does not require any security or collateral to support its receivables.

2.5. Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, control has been transferred, the fee is fixed or determinable, and collectability is reasonably assured. In instances where final acceptance of the product is specified by the customer, revenue is deferred until all acceptance criteria have been met. The Company's primary source of revenue is the subscription fee.

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its arrangements:

- Identify the contract with a customer.
- Identify the performance obligations in the contract.
- Determine the transaction price.
- Allocate the transaction price to performance obligations in the contract, and
- Recognize revenue as the performance obligation is satisfied.

2.6. Fair Value of Financial Instruments

Financial Accounting Standards Board ("FASB") guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows:

Rejuvine Life Sciences, Inc.

Notes to the Financial Statements (Unaudited)

As of December 31, 2023

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active).

Level 3 - Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.

3. EQUITY

The company is authorized to issue 50,000,000 shares of common shares at \$0.0001 par value. The company has no common shares issued and outstanding as of December 31, 2023.

4. SUBSEQUENT EVENTS

The Company intends to initiate a Regulation A offering of its series membership interests in 2024.

Management has evaluated all subsequent events through December 31, 2023, the date the financial statement was available to be issued. There are no other material events requiring disclosure or adjustment to the financial statement. The Company intends to initiate a Regulation A offering of its series membership interests in 2024.

Management has evaluated all subsequent events through December 31, 2023, the date the financial statement was available to be issued. There are no other material events requiring disclosure or adjustment to the financial statement.

5. GOING CONCERN

The accompanying balance sheet has been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses of (\$205,500) last year and negative cash flow from operations. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The shareholders are financing the operating activities of the company during the 2023 and 2024, and as discussed in note 4, the company intends to and have taken a series of steps to initiate a Regulation A offering of its series membership interests in 2024 and deploy such capital to produce profitable operating results.

Rejuvine Life Sciences, Inc.

Notes to the Financial Statements (Unaudited)

As of December 31, 2023

No assurance can be given that the Company will be successful in these efforts. The balance sheet does not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

6. INTELLECTUAL PROPERTY

On September 2023, the company signed multiple agreements with Daisy Technologies Pte. Limited to purchase the Intellectual Property Rights and all related assets to the Intellectual Property. The purchase occurred and the Intellectual Property Rights has been transferred into the company as per the signed agreement, for the total amount of \$4,000,000.

The Company is the owner for the exclusive rights to use these Intellectual Property as intangible assets. As such, these assets do have an indefinite life. The Company reviews the currently held intangible assets on an annual basis for impairment to determine if an adjustment is required. As the current intangible assets are working no impairment adjustment was considered necessary as of December 31, 2023.

7. NOTES PAYABLE

The company had a non-interest-bearing note for the purchase of the Intellectual Property Rights for the amount on \$3,910,000 as of December 31, 2023. The company will settle the notes based on availability of cash and the company's ability to pay its debts.

8. INVENTORY

As per Accounting Standards Codification (ASC) Topic 330: Inventory, the company accounts for its inventory in FIFO method and the lower of its cost or Net Realizable value (NRV).

The company's inventory consists of an item of raw material such as garlic, Krewsano and Osrasano, for the amount of \$79,352, which is recorded at its cost, and no impairment is required as it is lower than its NRV.

Also the company's inventory consists of Stock on produced Skordo Plus boxes which costs the company \$113,700, the management decided to that the Net Realizable Value (NRV) of the finished inventory is less than the books cost, and decided to record and impairment of \$18,950 at December 31, 2023.

Rejuvine Life Sciences, Inc.

Notes to the Financial Statements (Unaudited)

As of December 31, 2023

The following table illustrates the Produced inventory as of December 31, 2023:

Description	Amount
<i>Raw Materials used in the production</i>	\$17,991
<i>+ Direct Labor</i>	\$22,342
<i>+ Overhead costs</i>	\$78,443
<i>= Cost of products produced</i>	\$118,776
<i>- Cost of Goods Sold</i>	\$5,076
<i>= Cost of Inventory</i>	\$113,700
<i>Net Realizable Value of Inventory</i>	\$94,750
<i>Impairment of Produced Inventory</i>	\$18,950